AU2023265031A1 - Bag3 and protein quality control in the brain - Google Patents

Bag3 and protein quality control in the brain Download PDF

Info

Publication number
AU2023265031A1
AU2023265031A1 AU2023265031A AU2023265031A AU2023265031A1 AU 2023265031 A1 AU2023265031 A1 AU 2023265031A1 AU 2023265031 A AU2023265031 A AU 2023265031A AU 2023265031 A AU2023265031 A AU 2023265031A AU 2023265031 A1 AU2023265031 A1 AU 2023265031A1
Authority
AU
Australia
Prior art keywords
bag3
vector
brain
promoter
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023265031A
Other languages
English (en)
Inventor
Arthur M. Feldman
Valerie MYERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University
Original Assignee
Temple University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University filed Critical Temple University
Publication of AU2023265031A1 publication Critical patent/AU2023265031A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023265031A 2022-05-03 2023-05-02 Bag3 and protein quality control in the brain Pending AU2023265031A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263337914P 2022-05-03 2022-05-03
US63/337,914 2022-05-03
PCT/US2023/020659 WO2023215266A1 (en) 2022-05-03 2023-05-02 Bag3 and protein quality control in the brain

Publications (1)

Publication Number Publication Date
AU2023265031A1 true AU2023265031A1 (en) 2024-11-28

Family

ID=88646932

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023265031A Pending AU2023265031A1 (en) 2022-05-03 2023-05-02 Bag3 and protein quality control in the brain

Country Status (11)

Country Link
US (1) US20250289858A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518882A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025514489A (cg-RX-API-DMAC7.html)
KR (1) KR20250010008A (cg-RX-API-DMAC7.html)
CN (1) CN119255814A (cg-RX-API-DMAC7.html)
AU (1) AU2023265031A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250880A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003318A1 (cg-RX-API-DMAC7.html)
IL (1) IL316559A (cg-RX-API-DMAC7.html)
MX (1) MX2024013495A (cg-RX-API-DMAC7.html)
WO (1) WO2023215266A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024265705A1 (en) * 2023-05-02 2025-11-20 Research Institute At Nationwide Children's Hospital Gene therapy for treatment of protein misfolding diseases
CN120478386B (zh) * 2025-07-18 2025-10-17 南京大学 一种用于预防、改善和/或治疗阿尔茨海默症的siRNA及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
WO2015117010A2 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure
CN109937045A (zh) * 2016-08-11 2019-06-25 天普大学-联邦高等教育系统 局部缺血/再灌注损伤
US20210353613A1 (en) * 2018-10-19 2021-11-18 Aclipse One Inc. Treatment of neurological disease
JP7595006B2 (ja) * 2018-11-04 2024-12-05 フィジーン、エルエルシー 脳卒中、慢性外傷性脳症、及び外傷性脳損傷を含む脳性低酸素症の治療
US20220088127A1 (en) * 2019-01-15 2022-03-24 Temple University - Of The Commonwealth System Of Higher Education Targeting the bag family for the treatment of neurodegenerative disease
WO2023069744A1 (en) * 2021-10-22 2023-04-27 Temple University Of The Commonwealth System Of Higher Education Bag3 methods and uses for treatment of inflammation

Also Published As

Publication number Publication date
JP2025514489A (ja) 2025-05-02
EP4518882A1 (en) 2025-03-12
IL316559A (en) 2024-12-01
CA3250880A1 (en) 2023-11-09
US20250289858A1 (en) 2025-09-18
KR20250010008A (ko) 2025-01-20
EP4518882A4 (en) 2026-04-22
WO2023215266A1 (en) 2023-11-09
MX2024013495A (es) 2025-02-10
CL2024003318A1 (es) 2025-03-21
CN119255814A (zh) 2025-01-03

Similar Documents

Publication Publication Date Title
EP3146982B1 (en) Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
EP3132042B1 (en) A method of treating peripheral neuropathies and motor neuron diseases
EP4518882A1 (en) Bag3 and protein quality control in the brain
US10849991B2 (en) Gene therapy for the treatment of a disease of retinal cone cells
JP7759174B2 (ja) 繊毛病のための遺伝子治療
US12583902B2 (en) DNA-binding domain transactivators and uses thereof
CA3203748A1 (en) Products and methods for inhibition of expression of peripheral myelin protein-22
TW202136515A (zh) 用於治療韓特氏病之腺相關病毒載體
US20250345464A1 (en) Gene therapy for treating neurodegenerative diseases
EP4286521A1 (en) Gene therapy for treating neurodegenerative diseases
US20230203534A1 (en) Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
WO2024245120A1 (en) Recombinant aav vectors for treating proteinopathies in central nervous system
US20260007774A1 (en) Aav-mediated delivery of rgs10 to microglia
WO2025076201A1 (en) Human-targeted zinc finger protein to treat angelman syndrome
WO2024102961A1 (en) Synthetic nucleic acids including astrocyte-directed promoter constructs and methods of using the same